Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences European Lab Automation

Samu Melkko's Biography



Samu Melkko, Investigator, Novartis

Sorry, There is currently no biography for this presenter.

Samu Melkko Image

Automated State-of-the-Art Compound Profiling for Protease Drug Targets

Thursday, 30 June 2011 at 14:15

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Proteases are an important class of targets for drug discovery, with several protease inhibitors in the clinic for various indications. Similar to the well-established processes used in high-throughput screening (HTS), an automated compound profiling process for proteases has been introduced enabling high quality data and short turnaround times. Optimized workflows and a modular set-up of the processes provide the flexibility needed to support the unique needs of target-class oriented drug discovery programs with tailored solutions.


Add to Calendar ▼2011-06-30 00:00:002011-07-01 00:00:00Europe/LondonEuropean Lab AutomationEuropean Lab Automation in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com